Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 13/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524337 | 0.94 | THRB (0.59) | THRBTDP1APEX1PDK2S100A4 | |
| SCHEMBL31396310 | 0.94 | THRB (0.59) | THRBTDP1APEX1PDK2S100A4 | |
| Bromide SCHEMBL27743798 | 0.92 | THRB (0.57) | THRBTDP1APEX1PDK2S100A4 | |
| Propanol SCHEMBL27803571 | 0.84 | THRB (0.46) | THRBTDP1APEX1PDK2 | |
| Bromomethane SCHEMBL208217 | 0.78 | THRB (0.88) | THRBTDP1APEX1PDK2S100A4 | |
| Bromomethane SCHEMBL209152 | 0.78 | THRB (0.55) | THRBTDP1APEX1PDK2S100A4 | |
| SCHEMBL393095 | 0.72 | THRB (0.59) | THRBTDP1APEX1PDK2S100A4 | |
| SCHEMBL27621788 | 0.72 | ALOX5 (0.41) | THRBTDP1 | |
| SCHEMBL18663304 | 0.72 | THRB (0.64) | THRBTDP1APEX1PDK2S100A4 | |
| SCHEMBL15691557 | 0.72 | THRB (0.64) | THRBTDP1APEX1PDK2S100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100015061-A1 | Pharmaceutical Compositions Based on Anticholinergics and Andolast | Boehringer Ingeheim International GmnH (DE) | 2010-01-21 | — | — | US | claimed |
| EP-1978955-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND ANDOLAST | Boehringer Ingelheim International GmbH (DE) | 2008-10-15 | — | — | EP | claimed |
| EP-1858554-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND PDE 5-INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-11-28 | — | — | EP | claimed |
| WO-2007077164-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND ANDOLAST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-12 | — | — | WO | claimed |
| US-20060204450-A1 | Pharmaceutical Compositions Based On Anticholinergics and PDE 5-Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-14 | — | — | US | claimed |
| WO-2006094924-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND PDE 5-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-14 | — | — | WO | claimed |
| US-6998406-B2 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-14 | — | — | US | claimed |
| US-20050020622-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-01-27 | — | — | US | claimed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ANOVENT PHARMACEUTICAL (U.S.), LLC (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20050020622-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-01-27 | — | — | US | disclosed |
| US-6815452-B2 | ANTIASTHMATIC AND ANTISPASMODIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Boehringer Ingelheim Pharma KG & Co GmbH (DE) | 2004-11-09 | — | — | US | disclosed |
| US-6790856-B2 | TROPANE 9-FLUORENE-9-CARBOXYLATE DERIVATIVES FOR TREATMENT ASTHMA, CHRONIC OBSTRACTIVE PULMONARY DISEASE, VAGALLY INDUCED SINUS BRADYCARDIA, HEART RHYTHM DISORDERS, SPASM IN URINARY OR GASTROINTESTINAL TRACTS AND MENSTRUAL PAIN | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-09-14 | — | — | US | disclosed |
| US-20040157832-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-08-12 | — | — | US | disclosed |
| US-20030199539-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | THRB 1526/4885TDP1 4831/4885APEX1 3837/4885 |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | CBS, DHPS, TPMT | THRB 2325/4885TDP1 4425/4885APEX1 2950/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | THRB 1526/4885TDP1 4831/4885APEX1 3837/4885 |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ADRB2, ADRB1, ADRA2B | THRB 1226/4885TDP1 4836/4885APEX1 1947/4885 |
| US-20060204450-A1 | Pharmaceutical Compositions Based On Anticholinergics and PDE 5-Inhibitors | PDE5A, PDE3A, PDE3B | THRB 3608/4885TDP1 598/4885APEX1 3911/4885 |
| US-20050020622-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | FPR1, AFF1, F12 | THRB 3332/4885TDP1 2753/4885APEX1 3742/4885 |
| US-20100015061-A1 | Pharmaceutical Compositions Based on Anticholinergics and Andolast | CHRM3, ACHE, CHRNA1 | THRB 2685/4885TDP1 2262/4885APEX1 4060/4885 |
| US-20030199539-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | AFF1, FPR1, AFF4 | THRB 3645/4885TDP1 3359/4885APEX1 4192/4885 |
| US-20040157832-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | FPR1, AFF1, FPR3 | THRB 3281/4885TDP1 2599/4885APEX1 3655/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | THRB 1526/4885TDP1 4831/4885APEX1 3837/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | THRB 1526/4885TDP1 4831/4885APEX1 3837/4885 |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | ADRB2, CHRM3, ADRB1 | THRB 804/4885TDP1 3302/4885APEX1 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.